Inhibition of either FoxO1 or FoxO3 is sufficient to increase the intracellular ROS level that further induces KSHV lytic reactivation and subsequently causes massive cell death of PEL both in vitro and in vivo, which provides new opportunities for PEL treatment. This evidence concerns the gene FOXO3 and primary effusion lymphoma.